Skip to main content
. 2024 Jan 2;21:1. doi: 10.1186/s12954-023-00919-2

Table 1.

Demographic and clinical characteristics of patients certified for medical cannabis

Total (n = 562) Purchased medical cannabis n = 253
(45%)
Did not purchase n = 309
(55%)
p value*
Age (years), mean (SD) 50.6 (13.5) 51.79 (14.4) 49.60 (12.6) 0.06
Gender: female, n (%) 349 (62.1) 165 (65.2) 184 (59.5) 0.16
Race, n (%) < 0.01
 Black 215 (40.6) 94 (39.5) 121 (41.4)
 White 56 (10.6) 35 (14.7) 21 (7.2)
 Asian 3 (0.6) 3 (1.3) 0 (0)
 Other 256 (48.3) 106 (44.5) 150 (51.4)
Ethnicity, n (%) 0.55
 Hispanic 241 (45.9) 131 (55.5) 153 (52.9)
 Non-Hispanic 284 (54.1) 105 (44.5) 136 (47.1)
Insurance, n (%) < 0.01
 Medicaid 265 (47.5) 101 (40.1) 164 (53.6)
 Medicare 193 (34.6) 96 (38.1) 97 (31.7)
 Private 100 (17.9) 55 (21.8) 45 (14.7)
Qualifying condition, n (%)
 Pain (back) 220 (39.1) 97 (38.3) 123 (39.8) 0.72
 Pain (other MSK) 190 (33.9) 88 (34.9) 102 (33) 0.63
 Pain (fibromyalgia) 30 (5.3) 14 (5.5) 16 (5.2) 0.85
 PTSD 17 (3) 9 (3.6) 8 (2.6) 0.50
 Other 105 (18.7) 47 (18.5) 58 (18.7) 0.95
Substance use, n (%)
 Current prescription opioid use 230 (40.9) 115 (45.5) 115 (37.2) 0.04
 Current unregulated cannabis use 297 (55.4) 111 (45.1) 186 (64.1) < 0.001
 Current tobacco use 187 (34.1) 60 (24.5) 127 (41.9) < 0.001
Chronic medical conditions, n (%)
 Hypertension 234 (41.6) 104 (41.1) 130 (42.1) 0.81
 Asthma 146 (26) 72 (28.5) 74 (23.9) 0.22
 Depression 145 (25.8) 70 (27.7) 75 (24.3) 0.36
 HIV 112 (19.9) 36 (14.2) 76 (24.6) < 0.01
 Arthritis 103 (18.3) 54 (21.3) 49 (15.9) 0.09
 Obesity 63 (11.2) 47 (18.6) 48 (15.5) 0.33
 Anxiety 89 (15.8) 44 (17.4) 45 (14.6) 0.36
 Diabetes 63 (11.2) 29 (11.5) 34 (11) 0.86
 Sickle cell 25 (4.4) 12 (4.7) 13 (4.2) 0.75

Statistically significant p-values are in bold

*Based on statistical tests comparing between participants who purchased medical cannabis and those who did not (independent t test for age, and chi-square test for all other variables)

MSK: Musculoskeletal; PTSD: Post-traumatic stress disorder